Back HCV Treatment

HCV Treatment

AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C

Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment success and provider satisfaction, according to a presentation at the 2016 AASLD Liver Meeting this month in Boston.

alt

Read more:

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full listing by topic

Liver Meeting 2016 website

11/20/16

alt

AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients

A new 3-drug coformulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2, or 3, with sustained response rates of 86% to 100% depending on treatment duration, according to study results presented this month at the AASLD Liver Meeting in Boston. Related studies showed that the combination is also effective for retreating people who were not cured with a previous course of direct-acting antivirals (DAAs).

alt

Read more:

AASLD 2016: U.S. Veterans Health System and Australia Show Potential for Rapid Hepatitis C Elimination

If sufficient money is available to pay for direct-acting antivirals (DAAs), the U.S. Veterans Health Administration could cure hepatitis C in the majority of veterans under its care within 3 years, and has already shown it has the capacity to start almost 7000 people on treatment in a single month, George Ioannou of the University of Washington in Seattle reported at the AASLD Liver Meeting last week in Boston.

alt

Read more:

AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C

A 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week regimen cured 96%-97% of people who experienced prior treatment failure on direct-acting antivirals (DAAs), according to a set of Phase 3 studies presented last week at the AASLD Liver Meeting in Boston.

alt

Read more: